Hsu YC - Search Results

1

Reply to: "Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues".

Hsu YC, Yip TC, Wong GL, Wu CY. Hsu YC, et al. J Hepatol. 2019 Apr;70(4):796-797. doi: 10.1016/j.jhep.2018.11.031. Epub 2019 Jan 8. J Hepatol. 2019. PMID: 30635241 No abstract available.

2

Long-term risk of recurrent peptic ulcer bleeding in patients with liver cirrhosis: a 10-year nationwide cohort study.

Hsu YC, Lin JT, Chen TT, Wu MS, Wu CY. Hsu YC, et al. Hepatology. 2012 Aug;56(2):698-705. doi: 10.1002/hep.25684. Epub 2012 Jul 6. Hepatology. 2012. PMID: 22378148

3

Pretreatment viral DNA stratifies mortality risk in patients receiving antiviral therapy for severe acute exacerbation of chronic hepatitis B.

Hsu YC, Wu CY, Chang CY, Tai CM, Tseng CH, Perng DS, Mo LR, Lin JT. Hsu YC, et al. Antivir Ther. 2013;18(2):221-8. doi: 10.3851/IMP2435. Epub 2012 Nov 6. Antivir Ther. 2013. PMID: 23128388

4

Association between nucleoside analogues and risk of hepatitis B virus–related hepatocellular carcinoma recurrence following liver resection.

Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT. Wu CY, et al. Among authors: hsu yc. JAMA. 2012 Nov 14;308(18):1906-14. doi: 10.1001/2012.jama.11975. JAMA. 2012. PMID: 23162861

5

Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.

Hsu YC, Ho HJ, Wu MS, Lin JT, Wu CY. Hsu YC, et al. Hepatology. 2013 Jul;58(1):150-7. doi: 10.1002/hep.26300. Epub 2013 May 15. Hepatology. 2013. PMID: 23389758

6

Antiviral therapy and hepatitis B virus-related hepatocellular carcinoma recurrence--reply.

Wu CY, Hsu YC. Wu CY, et al. Among authors: hsu yc. JAMA. 2013 Feb 27;309(8):766-7. doi: 10.1001/jama.2013.574. JAMA. 2013. PMID: 23443431 No abstract available.

7

Reply: To PMID 23389758.

Hsu YC, Wu CY. Hsu YC, et al. Hepatology. 2014 Apr;59(4):1652-3. doi: 10.1002/hep.26691. Epub 2014 Feb 18. Hepatology. 2014. PMID: 24038021 No abstract available.

8

Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients.

Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Hsu YC, et al. Hepatology. 2014 Apr;59(4):1293-302. doi: 10.1002/hep.26892. Epub 2014 Feb 18. Hepatology. 2014. PMID: 24122848 Clinical Trial.

9

Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.

Hsu YC, Wu CY, Lane HY, Chang CY, Tai CM, Tseng CH, Lo GH, Perng DS, Lin JT, Mo LR. Hsu YC, et al. J Antimicrob Chemother. 2014 Jul;69(7):1920-7. doi: 10.1093/jac/dku041. Epub 2014 Feb 26. J Antimicrob Chemother. 2014. PMID: 24576950

10

Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection.

Hsu YC, Ho HJ, Huang YT, Wang HH, Wu MS, Lin JT, Wu CY. Hsu YC, et al. Gut. 2015 Mar;64(3):495-503. doi: 10.1136/gutjnl-2014-308163. Epub 2014 Nov 14. Gut. 2015. PMID: 25398770

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,546 results

Search Page

Filters